Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access [Yah...
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Cingulate Inc. (CING)
Company Research
Source: Yahoo! Finance
Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that longstanding Cingulate investor and board member Peter J. Werth will join Cingulate Chairman and CEO Shane J. Schaffer in a live Benzinga All Access event on Friday May 3, 2024 , at 12:10 p.m. EST Mr. Werth, Founder and CEO of ChemWerth Inc., will discuss his background as a successful pharmaceutical executive and entrepreneur, as well as his perspective on capital markets, the biotech industry, and his vision for Cingulate. Dr. Schaffer will provide a company overview and recap recent Cingulate clinical and business updates. The event may be viewed live on Benzinga's YouTube channel, Benzinga All Access and will also be available for viewing on Cingulate's website at cingulate.com/investors Who: Cingulate Investor & Board Member Peter J. Werth and Cingulate Chairman & CEO Shane J. Schaffer What: Benzinga All Live Access Whe
Show less
Read more
Impact Snapshot
Event Time:
CING
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CING alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CING alerts
High impacting Cingulate Inc. news events
Weekly update
A roundup of the hottest topics
CING
News
- $10.9 Billion Attention Deficit Hyperactivity Disorder (ADHD) Opportunity Assessment and Forecasts 2022-2024 & 2032: Epidemiology, Symptoms, Diagnosis, Disease Management, Revenue, Unmet Needs [Yahoo! Finance]Yahoo! Finance
- FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD [Yahoo! Finance]Yahoo! Finance
- FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHDGlobeNewswire
- Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update [Yahoo! Finance]Yahoo! Finance
- Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateGlobeNewswire
CING
Sec Filings
- 6/18/24 - Form PRE
- 6/18/24 - Form 8-K
- 6/13/24 - Form 4
- CING's page on the SEC website